Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

NCT04383275 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

356

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: capecitabine and trastuzumab
DRUG: endocrine therapy and trastuzumab

Sponsor

Fudan University